"Maintenance Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.
Descriptor ID |
D060046
|
MeSH Number(s) |
E02.319.509
|
Concept/Terms |
Maintenance Chemotherapy- Maintenance Chemotherapy
- Chemotherapies, Maintenance
- Chemotherapy, Maintenance
- Maintenance Chemotherapies
|
Below are MeSH descriptors whose meaning is more general than "Maintenance Chemotherapy".
Below are MeSH descriptors whose meaning is more specific than "Maintenance Chemotherapy".
This graph shows the total number of publications written about "Maintenance Chemotherapy" by people in this website by year, and whether "Maintenance Chemotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 1 | 3 | 4 |
2013 | 0 | 4 | 4 |
2014 | 0 | 3 | 3 |
2015 | 0 | 1 | 1 |
2016 | 2 | 4 | 6 |
2017 | 1 | 2 | 3 |
2018 | 2 | 5 | 7 |
2019 | 3 | 6 | 9 |
2020 | 3 | 6 | 9 |
2021 | 1 | 7 | 8 |
2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Maintenance Chemotherapy" by people in Profiles.
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 Aug 29; 144(9):955-963.
-
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 01; 7(1):28-37.
-
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
-
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leuk Res. 2021 12; 111:106736.
-
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 09 30; 385(14):1280-1291.
-
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021 Jul 05; 15(7):1130-1141.
-
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4.